Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases
Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients
NEW YORK , April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will...
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline
NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB). Such investors are advised...
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. (“NUVB” or “the Company”) (NYSE:...
NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB). Such investors are advised...
Clinical data demonstrate IBTROZI's unprecedented durability in TKI-naïve advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) now increased to...
NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB). Such investors are advised...
NEW YORK , March 6, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) ...